Cargando…

A novel NHEJ gene signature based model for risk stratification and prognosis prediction in hepatocellular carcinoma

BACKGROUND: Non-homologous DNA end joining (NHEJ) is the predominant DNA double-strand break (DSB) repair pathway in human. However, the relationship between NHEJ pathway and hepatocellular carcinoma (HCC) is unclear. We aimed to explore the potential prognostic role of NHEJ genes and to develop an...

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, Zhu, Huang, Zhenkun, Shi, Yunxing, Yuan, Yichuan, Niu, Yi, Li, Binkui, Yuan, Yunfei, Qiu, Jiliang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10071660/
https://www.ncbi.nlm.nih.gov/pubmed/37016451
http://dx.doi.org/10.1186/s12935-023-02907-9
_version_ 1785019239962247168
author Lin, Zhu
Huang, Zhenkun
Shi, Yunxing
Yuan, Yichuan
Niu, Yi
Li, Binkui
Yuan, Yunfei
Qiu, Jiliang
author_facet Lin, Zhu
Huang, Zhenkun
Shi, Yunxing
Yuan, Yichuan
Niu, Yi
Li, Binkui
Yuan, Yunfei
Qiu, Jiliang
author_sort Lin, Zhu
collection PubMed
description BACKGROUND: Non-homologous DNA end joining (NHEJ) is the predominant DNA double-strand break (DSB) repair pathway in human. However, the relationship between NHEJ pathway and hepatocellular carcinoma (HCC) is unclear. We aimed to explore the potential prognostic role of NHEJ genes and to develop an NHEJ-based prognosis signature for HCC. METHODS: Two cohorts from public database were incorporated into this study. The Kaplan–Meier curve, the Least absolute shrinkage and selection operator (LASSO) regression analysis, and Cox analyses were implemented to determine the prognostic genes. A NHEJ-related risk model was created and verified by independent cohorts. We derived enriched pathways between the high- and low-risk groups using Gene Set Enrichment Analysis (GSEA). CIBERSORT and microenvironment cell populations-counter algorithm were used to perform immune infiltration analysis. XRCC6 is a core NHEJ gene and immunohistochemistry (IHC) was further performed to elucidate the prognostic impact. In vitro proliferation assays were conducted to investigate the specific effect of XRCC6. RESULTS: A novel NHEJ-related risk model was developed based on 6 NHEJ genes and patients were divided into distinct risk groups according to the risk score. The high-risk group had a poorer survival than those in the low-risk group (P < 0.001). Meanwhile, an obvious discrepancy in the landscape of the immune microenvironment also indicated that distinct immune status might be a potential determinant affecting prognosis as well as immunotherapy reactiveness. High XRCC6 expression level associates with poor outcome in HCC. Moreover, XRCC6 could promote HCC cell proliferation in vitro. CONCLUSIONS: In brief, this work reveals a novel NHEJ-related risk signature for prognostic evaluation of HCC patients, which may be a potential biomarker of HCC immunotherapy. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12935-023-02907-9.
format Online
Article
Text
id pubmed-10071660
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-100716602023-04-05 A novel NHEJ gene signature based model for risk stratification and prognosis prediction in hepatocellular carcinoma Lin, Zhu Huang, Zhenkun Shi, Yunxing Yuan, Yichuan Niu, Yi Li, Binkui Yuan, Yunfei Qiu, Jiliang Cancer Cell Int Research BACKGROUND: Non-homologous DNA end joining (NHEJ) is the predominant DNA double-strand break (DSB) repair pathway in human. However, the relationship between NHEJ pathway and hepatocellular carcinoma (HCC) is unclear. We aimed to explore the potential prognostic role of NHEJ genes and to develop an NHEJ-based prognosis signature for HCC. METHODS: Two cohorts from public database were incorporated into this study. The Kaplan–Meier curve, the Least absolute shrinkage and selection operator (LASSO) regression analysis, and Cox analyses were implemented to determine the prognostic genes. A NHEJ-related risk model was created and verified by independent cohorts. We derived enriched pathways between the high- and low-risk groups using Gene Set Enrichment Analysis (GSEA). CIBERSORT and microenvironment cell populations-counter algorithm were used to perform immune infiltration analysis. XRCC6 is a core NHEJ gene and immunohistochemistry (IHC) was further performed to elucidate the prognostic impact. In vitro proliferation assays were conducted to investigate the specific effect of XRCC6. RESULTS: A novel NHEJ-related risk model was developed based on 6 NHEJ genes and patients were divided into distinct risk groups according to the risk score. The high-risk group had a poorer survival than those in the low-risk group (P < 0.001). Meanwhile, an obvious discrepancy in the landscape of the immune microenvironment also indicated that distinct immune status might be a potential determinant affecting prognosis as well as immunotherapy reactiveness. High XRCC6 expression level associates with poor outcome in HCC. Moreover, XRCC6 could promote HCC cell proliferation in vitro. CONCLUSIONS: In brief, this work reveals a novel NHEJ-related risk signature for prognostic evaluation of HCC patients, which may be a potential biomarker of HCC immunotherapy. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12935-023-02907-9. BioMed Central 2023-04-04 /pmc/articles/PMC10071660/ /pubmed/37016451 http://dx.doi.org/10.1186/s12935-023-02907-9 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Lin, Zhu
Huang, Zhenkun
Shi, Yunxing
Yuan, Yichuan
Niu, Yi
Li, Binkui
Yuan, Yunfei
Qiu, Jiliang
A novel NHEJ gene signature based model for risk stratification and prognosis prediction in hepatocellular carcinoma
title A novel NHEJ gene signature based model for risk stratification and prognosis prediction in hepatocellular carcinoma
title_full A novel NHEJ gene signature based model for risk stratification and prognosis prediction in hepatocellular carcinoma
title_fullStr A novel NHEJ gene signature based model for risk stratification and prognosis prediction in hepatocellular carcinoma
title_full_unstemmed A novel NHEJ gene signature based model for risk stratification and prognosis prediction in hepatocellular carcinoma
title_short A novel NHEJ gene signature based model for risk stratification and prognosis prediction in hepatocellular carcinoma
title_sort novel nhej gene signature based model for risk stratification and prognosis prediction in hepatocellular carcinoma
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10071660/
https://www.ncbi.nlm.nih.gov/pubmed/37016451
http://dx.doi.org/10.1186/s12935-023-02907-9
work_keys_str_mv AT linzhu anovelnhejgenesignaturebasedmodelforriskstratificationandprognosispredictioninhepatocellularcarcinoma
AT huangzhenkun anovelnhejgenesignaturebasedmodelforriskstratificationandprognosispredictioninhepatocellularcarcinoma
AT shiyunxing anovelnhejgenesignaturebasedmodelforriskstratificationandprognosispredictioninhepatocellularcarcinoma
AT yuanyichuan anovelnhejgenesignaturebasedmodelforriskstratificationandprognosispredictioninhepatocellularcarcinoma
AT niuyi anovelnhejgenesignaturebasedmodelforriskstratificationandprognosispredictioninhepatocellularcarcinoma
AT libinkui anovelnhejgenesignaturebasedmodelforriskstratificationandprognosispredictioninhepatocellularcarcinoma
AT yuanyunfei anovelnhejgenesignaturebasedmodelforriskstratificationandprognosispredictioninhepatocellularcarcinoma
AT qiujiliang anovelnhejgenesignaturebasedmodelforriskstratificationandprognosispredictioninhepatocellularcarcinoma
AT linzhu novelnhejgenesignaturebasedmodelforriskstratificationandprognosispredictioninhepatocellularcarcinoma
AT huangzhenkun novelnhejgenesignaturebasedmodelforriskstratificationandprognosispredictioninhepatocellularcarcinoma
AT shiyunxing novelnhejgenesignaturebasedmodelforriskstratificationandprognosispredictioninhepatocellularcarcinoma
AT yuanyichuan novelnhejgenesignaturebasedmodelforriskstratificationandprognosispredictioninhepatocellularcarcinoma
AT niuyi novelnhejgenesignaturebasedmodelforriskstratificationandprognosispredictioninhepatocellularcarcinoma
AT libinkui novelnhejgenesignaturebasedmodelforriskstratificationandprognosispredictioninhepatocellularcarcinoma
AT yuanyunfei novelnhejgenesignaturebasedmodelforriskstratificationandprognosispredictioninhepatocellularcarcinoma
AT qiujiliang novelnhejgenesignaturebasedmodelforriskstratificationandprognosispredictioninhepatocellularcarcinoma